ClinicalTrials.gg
RecruitingNCT07216105Updated Sep 2, 2026

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

A Phase 1 interventional study of FT836 and Cetuximab in Non-Small Cell Lung Cancer, Colorectal Cancer and Breast Cancer, sponsored by Fate Therapeutics. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Fate Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
119
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
959th of 2,998
119 · median 56
Started
2025
with 148 others
Phase 1
927 of 3,371
134 open now
Primary completion
2028-01
later than 539 of 892 live
Registered
3,230th of 3,371
by date

Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 959th largest by planned enrollment of the 2,998 interventional ones that give a count, is one of 149 that started in 2025, is one of 927 in phase 1, reaches primary completion later than 539 of the 892 other live ones, and was the 3,230th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 with or without chemotherapy and/or trastuzumab or cetuximab

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Endometrial Carcinoma
  • Head and Neck Squamous Cell Carcinoma

Keywords

  • HNSCC, NSCLC, CRC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For all regimens, disease that is not amenable to curative therapy and that has or progressed following at least one line of prior systemic therapy.
  • Evidence of adequate organ function as determined by all of the following:

    • (ANC) >1000/µL without growth factor support within 7 days prior to start of first study intervention
    • count ≥75,000/µL without transfusion support within 14 days prior to start of first study intervention
    • Estimated ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method
    • Total ≤1.5 × (ULN); for participants with documented Gilbert syndrome, total bilirubin must be ≤3 ×ULN
    • (AST) ≤3 × ULN or alanine transaminase (ALT) ≤3 × ULN; in participants with documented liver , AST or ALT ≤5 × ULN
    • Alkaline phosphatase (ALP) ≤2.5 × ULN; in participants with documented liver or bone metastases, ALP ≤5 × ULN
    • Oxygen saturation >90% on room air
  • (ECOG) Performance Status 0 or 1.
  • Presence of by , v1.1 assessed within 28 days prior to start of first study intervention.
  • Presence of baseline safely accessible lesions of adequate size for on-treatment (exceptions for lesion size may be granted with medical monitor approval) and participant willingness to undergo protocol prescribed on-treatment biopsies.

Exclusion criteria

Exclusion Criteria:

  • cardiovascular disease including any of the following: uncontrolled/ unstable cardiac arrhythmias, myocardial infarction within 6 months prior to start of first study intervention, unstable angina or congestive heart failure of (NYHA) Grade 2 or higher, or cardiac \<50%.
  • Receipt of any biological therapy, chemotherapy, therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter.
  • Known active central nervous system (CNS) involvement by . Participants with prior CNS involvement from their malignancy must have completed effective treatment of their CNS disease with no symptoms of disease in the absence of treatment and at least stable findings on relevant CNS imaging and no evidence of for at least 4 weeks prior to study enrollment.
  • Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions within 6 months prior to study enrollment.
  • Currently receiving or likely to require systemic therapy (e.g., prednisone ≥5 mg daily) for any reason from start of first study intervention to Day 29 with the exception of corticosteroids as a premedication for chemotherapy side effects per institutional standard of care or as mandated by the protocol.
  • Any history of Grade ≥3 immune-related AE or Grade ≥2 eye toxicity attributed to prior cancer immunotherapy, other than endocrinopathy managed with replacement therapy or asymptomatic elevation of serum amylase or lipase.
  • Grade ≥2 peripheral neuropathy limiting instrumental activities of daily living.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
119 participants (estimated)

Study arms

  • Experimental
    Regimen A

    CY/FLU followed by FT836

    Drug: FT836

  • Experimental
    Regimen B

    Standard-of-care (SOC) chemotherapy followed by FT836

    Drug: FT836

  • Experimental
    Regimen C

    FT836 combined with cetuximab

    Drug: FT836 · Drug: Cetuximab

  • Experimental
    Regimen D

    CY/FLU followed by FT836 combined with cetuximab

    Drug: FT836 · Drug: Cetuximab

  • Experimental
    Regimen D1

    SOC chemotherapy followed by FT836 combined with cetuximab

    Drug: FT836 · Drug: Cetuximab

  • Experimental
    Regimen E

    FT836 combined with trastuzumab

    Drug: FT836 · Drug: Trastuzumab

  • Experimental
    Regimen F

    CY/FLU followed by FT836 combined with trastuzumab

    Drug: FT836 · Drug: Trastuzumab

  • Experimental
    Regimen F1

    SOC chemotherapy followed by FT836 combined with trastuzumab

    Drug: FT836 · Drug: Trastuzumab

Interventions

  • DrugFT836

    FT836 drug product is administered as an intravenous infusion on multiple days schedule at treatment cycle.

  • Cetuximab administration will begin on Day -4 at the recommended initial dose of 400 mg/m2 as a 120-minute IV infusion

  • Trastuzumab administration will begin on Day -4 at an initial dose of 4 mg/kg as a 90-minute IV infusion.

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs)

    The number of participants experiencing ≥1 DLT will be reported.

    Time frame: From Day 1 through Day 29 of Cycle 1( each cycle is 56 days)

  2. Severity of DLTs

    The severity of DLTs will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, v5.0).

    Time frame: From Day 1 through Day 29 of Cycle 1( each cycle is 56 days)

Secondary outcomes

  1. Overall Response Rate (ORR)

    Participants will be classified into the following tumor response categories: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE) per RECIST v1.1. The best overall response (BOR) will be summarized for the efficacy evaluable population. ORR is defined as the percentage of participants who achieve a PR or better during the study prior to any subsequent off-protocol anti-cancer therapy.

    Time frame: Up to approximately 24 months

  2. Duration of Response (DOR)

    The DOR is defined as the time from first objective response to disease progression or death from any cause.

    Time frame: Up to approximately 24 months

  3. Progression-Free Survival (PFS)

    PFS is defined as the time from first study intervention to progressive disease or death from any cause.

    Time frame: Up to approximately 24 months

  4. Overall Survival (OS)

    OS is defined as the time from first dose of study intervention to death from any cause.

    Time frame: Up to approximately 24 months

07

Study locations

5 of 5 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2028, 26 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 26 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2025
First posted
Oct 14, 2025
StartActual
Nov 4, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2030
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07216105
Lead sponsor
Fate Therapeutics
Responsible party
Sponsor
First posted
Oct 14, 2025
Start date
Nov 4, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2030 (estimated)
Last update
Sep 2, 2026

Study contacts

Fate Trial Disclosure
Contact
FateTrialDisclosure@fatetherapeutics.com
858-875-1800
Lilly Wong, PhD
study director · Fate Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion